TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
8.73
+0.06 (0.69%)
Oct 9, 2025, 1:30 PM CST
0.69%
Market Cap6.27B
Revenue (ttm)40.68M
Net Income (ttm)-242.17M
Shares Out717.84M
EPS (ttm)-0.34
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume803,046
Average Volume1,760,668
Open8.69
Previous Close8.67
Day's Range8.67 - 8.80
52-Week Range7.44 - 14.75
Beta0.13
RSI44.35
Earnings DateNov 12, 2025

About TPEX:4157

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B, and avian influenza H7N9; Furaprevir, a HCV protease inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4157
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.